Literature DB >> 4089523

Fasting plasma caffeine concentration. A guide to the severity of chronic liver disease.

A Wahlländer, E Renner, R Preisig.   

Abstract

Fasting plasma caffeine concentrations (FPCC) were measured in 86 outpatients being examined for suspected or known liver disease. Seven patients (8%) who avoided caffeine consumption had nonmeasurable FPCC; they were dropped from further consideration. The remaining 79 subjects were divided into 4 diagnostic groups: surgical shunt (n = 11); alcoholic, posthepatitic, or primary biliary cirrhosis (n = 29); miscellaneous liver disease (n = 23); and normal liver (n = 16). FPCC was highest (mean, 17.8 mumol/l) in the shunt group, followed by the cirrhosis (12.3), miscellaneous liver diseases (4.6), and normal liver (2.1) groups. FPCC seemed to reflect severity of functional impairment, further supported by highly significant correlations with quantitative liver function tests, such as aminopyrine breath test (Rs = -0.89; n = 66), indocyanine green disappearance (Rs = -0.85; n = 65), and galactose elimination capacity (Rs = -0.70; n = 75). A careful dietary history showed no significant difference in caffeine consumption among the groups. It is suggested that in regular coffee drinkers FPCC might serve as a simple and convenient guide to the severity of functional impairment in chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4089523     DOI: 10.3109/00365528509088884

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  A review of new approaches to assessing hepatic function in animals.

Authors:  C E Cornelius
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

2.  Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism.

Authors:  H Wietholtz; T Zysset; K Kreiten; D Kohl; R Büchsel; S Matern
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Pharmacokinetics of isradipine in patients with chronic liver disease.

Authors:  J Cotting; J Reichen; K Kutz; R Laplanche; E Nüesch
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.

Authors:  S Krähenbühl; P Grass; A Surve; K Kutz; J Reichen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.